Author:
Rutherford Claudia,Costa Daniel S J,King Madeleine T,Smith David P,Patel Manish I
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Cheluvappa R, Smith DP, Cerimagic S, Patel MI (2014) A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. Int Urol Nephrol 46(7):1351–1360
2. Heney NM (1992) Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19(3):429–433
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. PharmacoEconomics 21(18):1315–1330
4. Zlotta AR, van Vooren JP, Huygen K, Drowart A, Decock M, Pirson M et al (2000) What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 37(4):470–477
5. Food and Drug Administration (2009) Patient reported outcome measures: use in medical product development to support labelling claims. US Department of Health & Human Support Food & Drug Administration, MD
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献